NCT05527717 (RESCUE-SHOCK) is a Phase 4 clinical trial of Culprit lesion only PCI in Cardiogenic Shock, sponsored by Samsung Medical Center.

Who is sponsoring NCT05527717?

NCT05527717 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT05527717?

Interventions in NCT05527717: Culprit lesion only PCI, Immediate multi-vessel PCI.

What condition does NCT05527717 study?

NCT05527717 studies Cardiogenic Shock, Acute Myocardial Infarction, Multi Vessel Coronary Artery Disease, Extracorporeal Membrane Oxygenation.

Is NCT05527717 still recruiting?

NCT05527717 is currently recruiting now. Last updated 6 November 2024.

Last reviewed 2024-11-06 · How we verify

NCT05527717: RESCUE-SHOCK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator

Recruiting now Phase 4 Last updated 6 November 2024

What this trial tests

Phase 4 trial testing Culprit lesion only PCI in Cardiogenic Shock in 560 participants. Currently enrolling.

Timeline

16 November 2022

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	560
Start date	16 November 2022
Primary completion	31 December 2027
Estimated completion	31 December 2028
Sites	1 location across South Korea

Drugs / interventions tested

Culprit lesion only PCI
Immediate multi-vessel PCI

Conditions studied

Cardiogenic Shock — all drugs for Cardiogenic Shock →
Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →
Multi Vessel Coronary Artery Disease — all drugs for Multi Vessel Coronary Artery Disease →
Extracorporeal Membrane Oxygenation — all drugs for Extracorporeal Membrane Oxygenation →

Sponsor

Samsung Medical Center

Who can join

19 and older, any sex, with Cardiogenic Shock or Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Culprit-Only Versus Immediate Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicating Advanced Cardiogenic Shock Requiring Venoarterial-Extracorporeal Membrane Oxygenation.
Choi KH, Yang JH, Park TK, Lee JM, et al · · 2023 · cited 10× · PMID 37158104 · DOI 10.1161/jaha.123.029792
Complete revascularization with percutaneous coronary intervention for acute coronary syndromes presenting with multivessel disease.
Reddy RK, Bernstein H, Howard JP, Ahmad Y. · · 2025 · PMID 40900649 · DOI 10.1097/hco.0000000000001250

Verify or expand the search:

Other recruiting trials for Cardiogenic Shock

Currently open trials in the same condition.

NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07345559 — Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock · NA · recruiting
NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
NCT07309029 — Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05527717 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 6 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05527717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing